Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: GlobeNewswire
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Nearly 50 Sites Activated Across U.S. with Strong Enthusiasm from InvestigatorsLymphodepletion Selection and Futility Analysis Shifted to 1H 2026 in Part Due to Site-Related Factors that Impacted Expected Pace of Screening Immediately Following Site ActivationOver 250 Patients Consented for MRD Screening to Date, with Nearly Half in the Last Three Months and Awaiting Completion of 1L Treatment as Earliest Activated Sites Build MomentumInternational Expansion of ALPHA3 Trial to Begin with Site Activations in Canada in Q2 2025 Phase 1 RESOLUTION Trial with ALLO-329 in Autoimmune Disease (AID) RESOLUTION Basket Trial in Rheumatology on Track for Mid-2025 StartProof-of-Concept Data Moved to 1H 2026 to Enable Inclusion of Both Biomarker and Clinical Data Phase 1 TRAVERSE Trial with ALLO-316 in Renal Cell Carcinoma (RCC) Updated Phase 1 Trial Results Will
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with CellectisGlobeNewswire
- Allogene Therapeutics Announces Participation in Upcoming Investor ConferencesGlobeNewswire
- Allogene: ALLO-316 Data In RCC Could Lead To Targeting Solid Tumors With CAR T [Seeking Alpha]Seeking Alpha
- Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business UpdateGlobeNewswire
ALLO
Earnings
- 11/6/25 - Beat
ALLO
Sec Filings
- 12/22/25 - Form 4
- 11/19/25 - Form 4
- 11/17/25 - Form 144
- ALLO's page on the SEC website